Attached files
file | filename |
---|---|
8-K - FORM 8-K - Vericel Corp | a58080e8vk.htm |
Exhibit 99.1
Aastrom Biosciences, Inc. Announces Proposed
Public Offering
Public Offering
Ann Arbor, MI, December 9, 2010 (4:00pm ET) Aastrom Biosciences, Inc. (NASDAQ: ASTM), a leading
developer of expanded autologous cellular therapies for the treatment of severe, chronic
cardiovascular diseases, today announced that it is commencing a public offering of its common
stock and warrants to purchase shares of its common stock. The Company intends to use the net
proceeds from the offering for general corporate purposes, including research and development
expenses such as expenses related to its Phase 3 CLI program, capital expenditures, working capital
and general administrative expenses.
Stifel Nicolaus Weisel is acting as sole book-running manager and Needham & Company, LLC and Roth
Capital Partners are acting as co-managers.
The offering is being made pursuant to an effective shelf registration statement that Aastrom filed
with the Securities and Exchange Commission, or the SEC, on November 12, 2010. A prospectus
supplement relating to the offering will be filed with the SEC. When available, copies of the
prospectus supplement and the prospectus relating to these securities may be obtained by contacting
Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco,
California 94104, Attention: General Counsel, (415) 364-2500. Electronic copies of the prospectus
supplement and accompanying prospectus will also be available on the website of the SEC at
http://www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy
shares of common stock and warrants of Aastrom Biosciences, Inc., nor shall there be any sale of
these securities in any state or jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of any such state or
jurisdiction.
About Aastrom Biosciences
Aastrom Biosciences is an emerging biotechnology company developing expanded autologous cellular therapies for use in the treatment of severe, chronic cardiovascular
Aastrom Biosciences is an emerging biotechnology company developing expanded autologous cellular therapies for use in the treatment of severe, chronic cardiovascular
- more -
diseases. The companys
proprietary cell-processing technology enables the manufacture of mixed-cell therapies expanded
from a patients own bone marrow and delivered directly to damaged tissues. Aastrom has advanced
its cell therapies into late-stage clinical development, including a planned Phase 3 clinical
program for the treatment of patients with critical limb ischemia and two ongoing Phase 2 clinical
trials in patients with dilated cardiomyopathy. For more information, please visit Aastroms
website at www.aastrom.com.
Media Contact
|
Investor Contact | |
Stephen Zoegall
|
Kimberli OMeara | |
Berry & Company
|
Aastrom Biosciences | |
212 2538881
|
734 9305777 | |
szoegall@berrypr.com
|
ir@aastrom.com |
This document contains forward-looking statements, within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995, including without limitation,
statements concerning Aastroms ability to successfully complete the proposed offering and its
planned Phase 3 clinical program, as well as other risks that are described in further detail in
the preliminary prospectus and our most recent Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q, and from time to time in other publicly available information regarding the Company.
These statements are often, but are not always, made through the use of words or phrases such as
anticipates, intends, estimates, plans, expects, we believe, we intend, and similar
words or phrases, or future or conditional verbs such as will, would, should, potential,
could, may, or similar expressions. Actual results may differ significantly from the
expectations contained in the forward-looking statements. These forward looking statements reflect
managements current views and Aastrom does not undertake to update any of these forward-looking
statements to reflect a change in its views or events or circumstances that occur after the date of
this release except as required by law.